title: Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients.
  
  
  METHODS
  In this Phase II trial, patients with unresectable stage III NSCLC were treated with the oral administration of UFT (400 mg/m(2)/d tegafur) on days 1-14 and days 29-42 whereas 80 mg/m(2) cisplatin was administered i.v. on days 8 and 36. Radiotherapy, with a total dose of 60 Gy, was delivered in 30 fractions from day 1.
  
  
  RESULTS
  Seventy patients were enrolled and eligible, as follows: 57 males/13 females; mean age 61 ranging from 36 to 74; performance status 0/1:45/25; stage IIIA/IIIB, 14/56. A complete response was observed in two patients and a partial response in 54 patients, and the overall response rate was 81% (95% confidence interval; 70-89%). The median survival, the 1- and 2-year survival rates were 16.5 months, 67% and 33%, respectively. Grade 3/4 leukopenia occurred in 14%/1% of the patients. Grades 3 non-hematological toxicities were only reported in three patients with nausea, two with esophagitis and one with pneumonitis whereas no grade 4 non-hematological toxicity was observed.
  
  
  CONCLUSIONS
  UFT plus cisplatin with concurrent radiotherapy is considered to be a feasible and effective treatment for locally advanced NSCLC patients. Additional study of this concurrent chemoradiotherapy is warranted.
authors.affiliation: Department of Thoracic Oncology, National Kyusyu Cancer Center, Fukuoka, Japan. yichinos@nk-cc.go.jp
authors.forename: Yukito
authors.initials: Y
authors.lastname: Ichinose
authors.forename: Yushi
authors.initials: Y
authors.lastname: Nakai
authors.forename: Shoji
authors.initials: S
authors.lastname: Kudoh
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Semba
authors.forename: Susumu
authors.initials: S
authors.lastname: Yoshida
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Nukiwa
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yamane
authors.forename: Hisanobu
authors.initials: H
authors.lastname: Niitani
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000494:pharmacology*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy; D012737:Sex Factors; D005641:Tegafur / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome; D014498:Uracil / Q000494:pharmacology*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005641:Tegafur; D014498:Uracil; D002945:Cisplatin